Shimadzu?s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a newly developed ion source and collision cell technology.
Shimadzu’s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a newly developed ion source and collision cell technology.
Trace level quantitation of multiple compounds
Shimadzu’s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a newly developed ion source and collision cell technology. As the flagship model of Shimadzu’s UFMS (Ultra-Fast Mass Spectrometry) product line, the LCMS-8050 features high sensitivity, high data quality and the world’s fastest data acquisition rates.
Delivering attogram-level (10-18 grams) sensitivity and possessing unsurpassed ruggedness, the LCMS-8050 achieves its improved sensitivity through two important technologies:
The world’s fastest data acquisition rates
The newly engineered high voltage power supply enables a maximum scan rate of 30,000 u/sec and a 5 msec polarity switching time, making the LCMS-8050 combined with Nexera UHPLC the ideal platform for laboratory productivity. It is now possible to include 1,000 events with up to 32 channels per event for a maximum of 32,000 MRMs per analysis.
User-friendly operation and easy maintenance
The LabSolutions LCMS Version 5.60 software provides seamless integration of HPLC and MS control. An automated MRM optimization routine allows unattended optimization of multiple compounds.
For more information please visit www.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Cooperating With Our Customers Across the US
May 13th 2025Highlighting the importance for our clients to prepurchase multi-year maintenance contracts, in order to avoid their machines breaking or stopping to work suddenly and unexpectedly, to minimize the risk of interrupted production and emergency maintenance costs.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
May 12th 2025Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines (Sealy 2021). Formulators need to consider a number of factors when scaling up novel LNP systems. These include flow rates that affect LNP particles, solvent removal, risk factors when changing equipment, and the impact of tangential flow filtration sensitivity. In this technical note, we discuss these factors and what needs to be considered when developing a cost- and time efficient large-scale process.